Kalligeros Markos, Henry Linda, Younossi Zobair M
Division of Gastroenterology and Hepatology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
The Global NASH Council, Washington, DC, United States of America; Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, VA, United States of America; Center for Outcomes Research in Liver Diseases, Washington, DC, United States of America.
Metabolism. 2024 Nov;160:156004. doi: 10.1016/j.metabol.2024.156004. Epub 2024 Aug 23.
Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant implications for oncogenesis. This review synthesizes current evidence on the association between MASLD and cancer risk, highlighting its role as a risk factor for both intrahepatic and extrahepatic malignancies. MASLD is increasingly recognized as a major cause of hepatocellular carcinoma (HCC), with its incidence rising in parallel with the prevalence of metabolic dysfunction. Furthermore, MASLD is associated with an elevated risk of various gastrointestinal cancers, including colorectal, esophageal, stomach, and pancreatic cancers. Beyond the digestive tract, evidence suggests that MASLD may also contribute to an increased risk of other cancers such as breast, prostate, thyroid, gynecological, renal and lung cancers. Understanding the mechanisms underlying these associations and the impact of MASLD on cancer risk is crucial for developing targeted screening and prevention strategies.
代谢功能障碍相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病（NAFLD），是一个日益引起全球健康关注的问题，对肿瘤发生具有重大影响。本综述综合了关于MASLD与癌症风险之间关联的现有证据，强调了其作为肝内和肝外恶性肿瘤风险因素的作用。MASLD日益被认为是肝细胞癌（HCC）的主要原因，其发病率与代谢功能障碍的患病率平行上升。此外，MASLD与包括结直肠癌、食管癌、胃癌和胰腺癌在内的各种胃肠道癌症的风险升高有关。除了消化道，有证据表明MASLD也可能导致其他癌症如乳腺癌、前列腺癌、甲状腺癌、妇科癌症、肾癌和肺癌的风险增加。了解这些关联背后的机制以及MASLD对癌症风险的影响对于制定有针对性的筛查和预防策略至关重要。
